Az ALK-pozitív tüdõrák korszerû diagnosztikája

Translated title of the contribution: Molecular diagnostics of ALK-positive lung cancer

J. Tímár, G. Lotz, E. Rásó, Judit Moldvay

Research output: Contribution to journalArticle

Abstract

ALK translocation is the 3rd most frequent genetic aberration in lung adenocarcinoma, and several inhibitors are now clinically available in first and second line settings. Accordingly, molecular diagnostics of ALK-positive lung cancer is very important and can be done with the rational combination of several methods. All international recommendations suggest that, except for cytological samples, screening technology for ALK-positive tumors is immunohistochemistry using a validated test. It is highly recommended that in case of ALK protein positive samples gene translocation must be confirmed by fluorescent in situ hybridization (FISH). In case of cytological samples FISH technique must be used as ALK diagnostics. In equivocal cases the genetic alteration of ALK can be confirmed by alternative molecular techniques such as next generation sequencing or RNAbased PCR methods. Upon administration of ALK inhibitors, acquired resistance is frequent which is mostly due to ALK amplification and/or mutation. It is evident that the diagnostics of these secondary ALK gene alterations must be done from recurrent tumors or circulating nucleic acids.

Original languageHungarian
Pages (from-to)301-311
Number of pages11
JournalMagyar onkologia
Volume61
Issue number3
Publication statusPublished - Sep 20 2017

Fingerprint

Molecular Pathology
Fluorescence In Situ Hybridization
Lung Neoplasms
Nucleic Acids
Genes
Neoplasms
Immunohistochemistry
Technology
Polymerase Chain Reaction
Mutation
Proteins
Adenocarcinoma of lung

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az ALK-pozitív tüdõrák korszerû diagnosztikája. / Tímár, J.; Lotz, G.; Rásó, E.; Moldvay, Judit.

In: Magyar onkologia, Vol. 61, No. 3, 20.09.2017, p. 301-311.

Research output: Contribution to journalArticle

@article{266a08785060497d966877ec8d1dbae7,
title = "Az ALK-pozit{\'i}v t{\"u}d{\~o}r{\'a}k korszer{\^u} diagnosztik{\'a}ja",
abstract = "ALK translocation is the 3rd most frequent genetic aberration in lung adenocarcinoma, and several inhibitors are now clinically available in first and second line settings. Accordingly, molecular diagnostics of ALK-positive lung cancer is very important and can be done with the rational combination of several methods. All international recommendations suggest that, except for cytological samples, screening technology for ALK-positive tumors is immunohistochemistry using a validated test. It is highly recommended that in case of ALK protein positive samples gene translocation must be confirmed by fluorescent in situ hybridization (FISH). In case of cytological samples FISH technique must be used as ALK diagnostics. In equivocal cases the genetic alteration of ALK can be confirmed by alternative molecular techniques such as next generation sequencing or RNAbased PCR methods. Upon administration of ALK inhibitors, acquired resistance is frequent which is mostly due to ALK amplification and/or mutation. It is evident that the diagnostics of these secondary ALK gene alterations must be done from recurrent tumors or circulating nucleic acids.",
author = "J. T{\'i}m{\'a}r and G. Lotz and E. R{\'a}s{\'o} and Judit Moldvay",
year = "2017",
month = "9",
day = "20",
language = "Hungarian",
volume = "61",
pages = "301--311",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - Az ALK-pozitív tüdõrák korszerû diagnosztikája

AU - Tímár, J.

AU - Lotz, G.

AU - Rásó, E.

AU - Moldvay, Judit

PY - 2017/9/20

Y1 - 2017/9/20

N2 - ALK translocation is the 3rd most frequent genetic aberration in lung adenocarcinoma, and several inhibitors are now clinically available in first and second line settings. Accordingly, molecular diagnostics of ALK-positive lung cancer is very important and can be done with the rational combination of several methods. All international recommendations suggest that, except for cytological samples, screening technology for ALK-positive tumors is immunohistochemistry using a validated test. It is highly recommended that in case of ALK protein positive samples gene translocation must be confirmed by fluorescent in situ hybridization (FISH). In case of cytological samples FISH technique must be used as ALK diagnostics. In equivocal cases the genetic alteration of ALK can be confirmed by alternative molecular techniques such as next generation sequencing or RNAbased PCR methods. Upon administration of ALK inhibitors, acquired resistance is frequent which is mostly due to ALK amplification and/or mutation. It is evident that the diagnostics of these secondary ALK gene alterations must be done from recurrent tumors or circulating nucleic acids.

AB - ALK translocation is the 3rd most frequent genetic aberration in lung adenocarcinoma, and several inhibitors are now clinically available in first and second line settings. Accordingly, molecular diagnostics of ALK-positive lung cancer is very important and can be done with the rational combination of several methods. All international recommendations suggest that, except for cytological samples, screening technology for ALK-positive tumors is immunohistochemistry using a validated test. It is highly recommended that in case of ALK protein positive samples gene translocation must be confirmed by fluorescent in situ hybridization (FISH). In case of cytological samples FISH technique must be used as ALK diagnostics. In equivocal cases the genetic alteration of ALK can be confirmed by alternative molecular techniques such as next generation sequencing or RNAbased PCR methods. Upon administration of ALK inhibitors, acquired resistance is frequent which is mostly due to ALK amplification and/or mutation. It is evident that the diagnostics of these secondary ALK gene alterations must be done from recurrent tumors or circulating nucleic acids.

UR - http://www.scopus.com/inward/record.url?scp=85066490813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066490813&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 301

EP - 311

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -